What is the recommended diagnostic workup and treatment plan for Hodgkin lymphoma, including staging, first‑line therapy for early‑stage favorable and unfavorable disease, advanced disease, and salvage options for relapse?

Hodgkin Lymphoma: Diagnostic Workup and Treatment

Diagnostic Workup

The diagnosis of Hodgkin lymphoma requires an excisional lymph node biopsy with immunohistochemistry, followed by comprehensive staging with PET/CT, laboratory evaluation, and bone marrow biopsy in select cases. 1, 2

Tissue Diagnosis

• Excisional lymph node biopsy is mandatory to provide adequate tissue for histological classification according to WHO criteria 1, 2
• Core needle biopsy may be adequate if diagnostic, but fine needle aspiration (FNA) alone is insufficient 1
• Immunohistochemistry is essential: Classical Hodgkin lymphoma shows CD30+, CD15+ (majority), CD3-, CD45-, with CD20+ in <40% of cases 1
• Classical Hodgkin lymphoma includes four subtypes: nodular sclerosis, mixed cellularity, lymphocyte-depleted, and lymphocyte-rich 1

Staging Evaluation

Mandatory staging procedures include: 1

• History and physical examination documenting B symptoms (fever >38°C, night sweats, unexplained weight loss >10% in 6 months), alcohol intolerance, pruritus, fatigue, and examination of all lymphoid regions 1, 2
• Laboratory tests: CBC with differential and platelets, ESR, LDH, liver function tests, albumin, BUN, creatinine 1
• Imaging: Chest X-ray, diagnostic CT of chest/abdomen/pelvis, and PET/CT scan 1, 2
• Bone marrow biopsy is required for stage IB, IIB, and stage III-IV disease 1

Staging laparotomy is not recommended 1

Pre-Treatment Assessment

• Cardiac evaluation: Echocardiography or MUGA scan to assess ejection fraction before doxorubicin-containing regimens 1, 3, 2
• Pulmonary function tests (including DLCO) if ABVD or BEACOPP planned 1, 3
• Pregnancy test for women of childbearing age 1, 2
• Fertility preservation counseling: Semen cryopreservation for men; IVF, ovarian tissue, or oocyte cryopreservation for women if chemotherapy or pelvic radiotherapy contemplated 1, 3

Risk Stratification

Patients are classified into three prognostic groups using Ann Arbor staging with risk factors: 1, 3

Early-Stage Favorable (Stage I-II without risk factors)

• No unfavorable risk factors present 1, 3

Early-Stage Unfavorable (Stage I-II with risk factors)

Unfavorable factors include: 1, 4, 3

• Bulky mediastinal mass (>1/3 thoracic width or >10 cm)
• Extranodal involvement
• ESR >50 (A symptoms) or >30 (B symptoms)
• ≥3 sites of disease
• Massive splenic involvement

Advanced Stage (Stage III-IV)

• Any stage III or IV disease 1

First-Line Treatment

Early-Stage Favorable Disease

The standard treatment is 2-4 cycles of ABVD followed by 30 Gy involved-field radiotherapy (IFRT). 1, 3

• Combined modality therapy: 2 cycles of ABVD plus IFRT achieves overall survival exceeding 90% at 5 years 1, 3
• ABVD alone (without radiotherapy) is a category 2B alternative for patients wishing to avoid radiation 1
• Restaging with PET/CT after chemotherapy is essential before proceeding to radiotherapy 1

Early-Stage Unfavorable Disease

The recommended treatment is 4 cycles of ABVD followed by 30 Gy IFRT. 1, 4, 3, 2

• This approach achieves tumor control and overall survival of 85-90% at 5 years 4, 3
• For patients under 60 years eligible for intensive treatment, consider 2 cycles of escalated BEACOPP followed by 2 cycles of ABVD and 30 Gy IFRT 4
• PET/CT restaging after chemotherapy guides radiotherapy decisions 1

Advanced-Stage Disease

The standard treatment is 6-8 cycles of ABVD or escalated BEACOPP, with radiotherapy reserved for bulky disease (>7.5 cm) or residual masses. 1, 3

• ABVD for 8 cycles remains a standard option 1
• Escalated BEACOPP may offer superior progression-free survival but requires long-term confirmation and carries higher toxicity, particularly infertility risk 1, 3
• Involved-field radiotherapy (30-36 Gy) should be applied only to initially bulky tumors or sites of residual disease after chemotherapy 1
• Newer agents including brentuximab vedotin and anti-PD-1 antibodies are now being incorporated into frontline therapy 5, 6

Response Assessment

Interim and end-of-treatment PET/CT scanning is critical for treatment optimization: 1, 3

• Interim PET after 2-4 cycles may guide treatment escalation or de-escalation, though this approach is not yet standard practice 3
• End-of-treatment PET/CT is necessary to confirm complete remission 4, 2
• Response criteria follow updated Cheson criteria: complete remission requires PET-negative status with any size residual masses permitted 1

Salvage Therapy for Relapsed/Refractory Disease

For most patients with relapsed disease, high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care. 3, 5, 6

Salvage Approach

• Salvage chemotherapy regimens include DHAP, EPOCH, or Dexa-BEAM 1
• High-dose chemotherapy with ASCT is standard for chemotherapy-sensitive relapse 3, 5, 7
• For post-ASCT relapse: Consider brentuximab vedotin, PD-1 blockade (nivolumab or pembrolizumab), non-myeloablative allogeneic transplant, or clinical trial participation 5, 6, 8

Follow-Up Protocol

Structured surveillance is essential to detect relapse and monitor for late effects: 1

• Years 1: History and physical examination every 3 months 1
• Years 2-3: Every 6 months 1
• Years 4+: Annually 1
• Laboratory tests and chest X-ray at 6,12, and 24 months, then as clinically indicated 1
• CT scans: Once to confirm remission status; routine surveillance CT not recommended except for residual disease evaluation 1
• Thyroid function (TSH) at 1,2, and 5 years for patients receiving neck irradiation 1
• Breast cancer screening for women receiving chest irradiation at premenopausal age, especially <25 years: clinical examination and mammography after age 40-50 1
• Long-term monitoring for cardiovascular disease and secondary malignancies 4

Critical Pitfalls to Avoid

• Never rely on FNA alone for diagnosis; excisional biopsy is mandatory 1, 2
• Do not omit PET/CT when available, as it significantly impacts staging and response assessment 1, 2
• Always provide fertility preservation counseling before treatment initiation, particularly for BEACOPP which carries high infertility risk 1, 3
• Do not skip baseline cardiac and pulmonary function testing before anthracycline and bleomycin-containing regimens 1, 3, 2
• Avoid routine surveillance CT scans beyond initial remission confirmation, as they increase radiation exposure without proven benefit 1